Salehi Omran Hossein, Balouchzadeh Amir, Dolatshahi Sina, Abrotan Saeed, Salehi Omran Mohammad Taghi, Saravi Mehrdad, Aboutalebzadeh Sara, Hedayati Goudarzi Mohammad Taghi
Department of Cardiology, Ayatollah Rouhani Hospital, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Neyshabur University of Medical Sciences, Neyshabur, Iran.
Caspian J Intern Med. 2025 Mar 11;16(2):233-238. doi: 10.22088/cjim.16.2.233. eCollection 2025.
Patients with moderate to severe chronic heart failure (CHF) are at high risk for cardiac mortality. Cardiac resynchronization therapy with defibrillators (CRT-D) as a potentially beneficial option can improve the clinical outcomes of such patients.
We conducted a single-arm clinical trial in which 48 patients with moderate to severe CHF were investigated regarding the beneficial outcome of CRT-D insertion. All participants were evaluated regarding different functional and echocardiographic factors including New York Heart Association (NYHA) functional class (FC), left ventricular ejection fraction (LVEF), mitral regurgitation (MR) as well as left ventricular end-systolic (LVESD) and end-diastolic (LVEDD) before and one month after the procedure. Furthermore, we investigated the influence of different variables including age, gender, and comorbidities on the aforementioned clinical and echocardiographic factors.
Of the 48 CHF patients included in our study, 24 (50%) were males and 24 (50%) were females. The mean ± standard deviation (range) of the participants' age was 55.6±6.5 (40-69) years. CRT-D insertion significantly improved all functional and echocardiographic factors in CHF patients. The participants had a mean±standard deviation (range) LVEF of 22.1±5.8% (10-30%) before CRT-D insertion. A follow-up echocardiography performed one month after the implantation of CRT-D demonstrated a significant increase in LVEF to 27.1±5.5% (15-38%) (<0.001). Additionally, echocardiography conducted one month after CRT-D insertion showed a reduction of LVESD from 6.8±0.5 cm (5.8-7.4 cm) to 6.2±0.5 cm (5.3-7.3 cm) (<0.001).
There is prominent evidence for CRT-D insertion in reducing symptoms of heart failure as well as improving different echocardiography variables in patients with moderate to severe CHF.
中重度慢性心力衰竭(CHF)患者心脏死亡风险很高。植入式心脏复律除颤器的心脏再同步治疗(CRT-D)作为一种潜在的有益选择,可以改善此类患者的临床结局。
我们进行了一项单臂临床试验,对48例中重度CHF患者植入CRT-D的有益结局进行了研究。所有参与者在手术前和术后1个月均就不同的功能和超声心动图因素进行了评估,包括纽约心脏协会(NYHA)心功能分级(FC)、左心室射血分数(LVEF)、二尖瓣反流(MR)以及左心室收缩末期内径(LVESD)和舒张末期内径(LVEDD)。此外,我们研究了年龄、性别和合并症等不同变量对上述临床和超声心动图因素的影响。
在我们纳入研究的48例CHF患者中,24例(50%)为男性,24例(50%)为女性。参与者的平均年龄±标准差(范围)为55.6±6.5(40-69)岁。植入CRT-D显著改善了CHF患者的所有功能和超声心动图因素。在植入CRT-D前,参与者的平均LVEF±标准差(范围)为22.1±5.8%(10-30%)。在植入CRT-D后1个月进行的随访超声心动图显示LVEF显著增加至27.1±5.5%(15-38%)(<0.001)。此外,在植入CRT-D后1个月进行的超声心动图显示LVESD从6.8±0.5 cm(5.8-7.4 cm)降至6.2±0.5 cm(5.3-7.3 cm)(<0.001)。
有显著证据表明,植入CRT-D可减轻中重度CHF患者的心力衰竭症状,并改善不同的超声心动图变量。